Evidence map›Paper›PMID 42583086›Full record

ArticleESMO gastrointestinal oncology2026

The EvIDHence study: real-world treatment patterns and safety outcomes in mutant and wild-type

V Sahai, J W Valle, N Fares, M Javle, I Ghanem, P Cerdà, I G Rapposelli, I G Jimenez, M A Gonzalez-Carmona, A Hollebecque and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ESMO gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

V SahaiDivision of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor.
J W ValleCholangiocarcinoma Foundation, Salt Lake City, USA.
N FaresDigestive Oncology Unit, Rangueil University Hospital, CHU Toulouse, Toulouse, France.
M JavleDepartment of Gastrointestinal Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, USA.
I GhanemDepartment of Medical Oncology, Hospital Universitario La Paz, Madrid, Spain.
P CerdàMedical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
I G RapposelliDepartment of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
I G JimenezMedical Oncology Department, Virgen del Rocío University Hospital, IBIS, Seville, Spain.
M A Gonzalez-CarmonaDepartment of Medicine I, University Hospital of Bonn, Bonn, Germany.
A HollebecqueEarly Drug Development Department, Gustave Roussy, Villejuif, France.
R Pazo CidMedical Oncology Department, Hospital Universitario Miguel Servet, Saragossa, Spain.
D H PalmerDepartment of Molecular and Clinical Cancer Medicine, Cancer Research UK Liverpool Experimental Cancer Medicine Centre, University of Liverpool and The Clatterbridge Cancer Centre, Liverpool, UK.
R VeraMedical Oncology Department, University Hospital of Navarra, Instituto de Investigación Sanitaria de Navarra, IdISNA, Pamplona, Navarra, Spain.
A Casadei-GardiniDepartment of Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy.
D MelisiInvestigational Cancer Therapeutics Clinical Unit, Università degli Studi di Verona and Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
J-F BlancDigestive Oncology Department, University Hospital of Bordeaux, Bordeaux, France.
L PerkhoferDepartment of Internal Medicine 1, University Hospital Ulm, Ulm, Germany.
A LamarcaDepartment of Medical Oncology, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
H GharbiMedical Affairs, Servier, Suresnes, France.
V Manuel-MinguezMedical Affairs, Servier, Suresnes, France.
R RobertMedical Affairs, Servier, Suresnes, France.
L RimassaDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Treatment options for cholangiocarcinoma (CCA) are limited, with poor overall survival (OS). The impact of molecular alterations on clinical outcomes in real-world practice is poorly understood. Patients and Methods: EvIDHence was a retrospective, descriptive, multicenter, international, chart review study investigating the natural disease course of patients with advanced/metastatic CCA who underwent mutant isocitrate dehydrogenase-1 (m Results: Sixty-three patients with CCA (31 m Conclusion: These real-world data highlight the poor prognosis of patients with CCA, regardless of

Indexed as

biomarker testingcholangiocarcinomaisocitrate dehydrogenase-1safetysurvivaltreatment patterns

Identifiers

PMID42583086
PMCPMC13459570

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.